Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono agrees new Crinone licensing deals

Merck Serono agrees new Crinone licensing deals

20th May 2010

Merck Serono has renewed its licensing deal with Columbia Laboratories over the international marketing rights to the fertility treatment Crinone.

Under the terms of the new deal, Merck Serono will sell the therapy, which is intended for infertile women with a progesterone deficiency, in countries outside the US for an additional five years.

The specifics of the agreement will be the same as the ones already in effect, allowing Merck Serono to continue selling the treatment in 63 countries.

Frank Condella Jr, Columbia’s president and chief executive officer, said he expects sales of the treatment to increase compared to 2009, thanks to rising demand for the drug in many growth markets.

He said: “We therefore look forward to a good royalty stream in 2010 and beyond as Merck Serono continues building Crinone’s presence in current markets and expanding its geographic reach.”

Earlier this month, Merck Serono granted funding support to a number of multiple sclerosis research projects in the UK, US and Australia as part of a charity collaboration.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.